Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy. It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the …
Sleeping Off Diabetic Retinopathy
Sharing results from a real-world single center study of patients with diabetic macular oedema (DMO) who wore a home-use sleep mask (Noctura 400) for 12 months PolyPhotonix, the manufacturer of the Noctura 400 – a treatment for diabetic retinopathy – recently completed a realworld study at an NHS hospital in the UK, which began in 2019. The study analyzed the …
AI-supported test can predict eye disease that leads to blindness
In a clinical trial of 113 patients led by researchers at Imperial College London and UCL, retinal imaging technology called Detection of Apoptosis in Retinal Cells (DARC) was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes reduced vision and blindness.The researchers believe that this technology could be …
iStent inject safe, efficacious in open-angle glaucoma
The iStent inject was safe and effective for treating multiple types of primary open-angle glaucoma individually and in conjunction with cataract surgery, according to data published in Journal of Cataract and Refractive Surgery.
Cataract surgery lowers IOP, medication use
Patients with ocular hypertension may benefit from cataract surgery, according to findings published in the American Journal of Ophthalmology.“Studies suggest that cataract surgery lowers IOP, and that this reduction is generally proportional to presurgical IOP. As well, several papers report a decrease in ocular hypotensive medications with cataract surgery,” Steven L. Mansberger, MD, MPH, ophthalmologist at Legacy Health in Portland, …
Dry eye disease cream demonstrates improvement, rapid onset of action in phase 2 trial
AXR-270 demonstrated ‘statically and clinically meaningful improvement’ in patients with dry eye disease associated with meibomian gland dysfunction, according to a press release from AxeroVision.
Visus Therapeutics to Host Its First Capital Markets Day Tomorrow
Visus Therapeutics will host its first Capital Markets Day for investors, analysts, and media tomorrow, August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue at 45th Street in New York City. During the Capital Markets Day, Ben Bergo, co-founder and chief executive officer; Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of …
Complexity Gaming Kicks Off Year-Long Partnership With Alcon
Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming.
Bausch Health Converts $10 Million Option Payment to Allegro into Equity Interest
Bausch Health has exercised its option to convert a $10 million upfront payment to Allegro Ophthalmics into a minor equity interest in Allegro, under the terms of an agreement announced in September 2020.
Nova Eye Medical Acquires Glaucoma Treatment Patents from Dallas Company
Australian company Nova Eye Medical announced Aug. 26 that it had completed an acquisition of a patent portfolio related to ab interno trabeculotomy from Innovative Glaucoma Solutions, a surgeon-owned company in Dallas. Nova Eye, which maintains a US base in Fremont, California, paid US $2 million up front and 1.7 million in Nova Eye shares for the acquisition. Tom Spurling, managing director …
